Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Voetsch, A; Pregartner, G; Berghold, A; Seitelberger, R; Schoerghuber, M; Toller, W; Mahla, E.
How do type of preoperative P2Y12 receptor inhibitor and withdrawal time affect bleeding.
Ann Thorac Surg. 2020;
PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Berghold Andrea
Mahla Elisabeth
Pregartner Gudrun
Schörghuber Michael
Toller Wolfgang
Vötsch Andreas
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Despite recommendations for standardized preoperative waiting of at least 3, 5, and 7 days for ticagrelor, clopidogrel, and prasugrel, respectively, there is still substantial inter-institutional variation in preoperative discontinuation of dual antiplatelet therapy in patients needing coronary artery bypass grafting (CABG). In 299 patients undergoing CABG ± valve intervention <7 days after last P2Y12 receptor inhibition, we evaluated calculated red blood cell loss. and Bleeding Academic Research Consortium (BARC)-4 bleeding. 83% of patients underwent CABG within <48 hours of last drug intake. Calculated blood loss was lower in patients on clopidogrel as compared to prasugrel or ticagrelor [1063 (690-1394) vs. 1351 (876-1829) vs. 1330 (994-1691) ml, p<0.001]. Overall, 135 (45%) patients sustained BARC-4 bleeding; incidence differed between groups (p=0.015) and was significantly higher in prasugrel-, as compared to clopidogrel-treated patients. In multivariable linear regression analysis, EuroSCORE II, aspirin dose, cardio-pulmonary-bypass time, drug withdrawal time, and type of P2Y12 receptor inhibitor were significantly associated with RBC loss. Compared to 0-24, >48 hours preoperative discontinuation substantially reduced calculated blood loss by 37-48% und BARC-4 bleeding by 58-71%, depending on P2Y12 receptor inhibitor. Exposure to prasugrel and ticagrelor within 24 hours before CABG increases both calculated blood loss and BARC-4 bleeding as compared to clopidogrel. Although a >48 hours discontinuation substantially reduced calculated blood loss and BARC-4 bleeding across all P2Y12 receptor inhibitors, our single center data further support strict adherence to the 2017 guidelines whenever justified by stable hemodynamics and non-jeopardized myocardium. Copyright © 2020. Published by Elsevier Inc.

© Med Uni Graz Impressum